Orca1

FDA inspection

SPI Pharma, Inc.: FDA inspection ending Sep 18, 2008

FDA inspection 536541 · Official Action Indicated (OAI) · Grand Haven, MI

Key facts

Inspection ID 536541
Firm SPI Pharma, Inc.
FEI number 1833292
Address 1711 Tiles Ct
City Grand Haven
State MI
ZIP 49417-2832
Fiscal year 2008
Inspection end date Sep 18, 2008
Classification Official Action Indicated (OAI)
Project area Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation|Generic Drug Evaluation
Product type Drugs

At a glance

  • None Citations
  • 1–9 Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 10–99 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Other inspections at this establishment

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections